Market Overview

UPDATE: Piper Jaffray Raises PT on BioMarin Pharmaceutical on Positive Trial Results

Share:
Related BMRN
Is BioMarin Still An Outperform At This Research Firm?
BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Merck KGaA-BioMarin's Kuvan may Undergo Label Update - Analyst Blog (Zacks)

In a report published Wednesday, Piper Jaffray analyst M Ian Somaiya reiterated an Overweight rating on BioMarin Pharmaceutical (NASDAQ: BMRN), and raised the price target from $64.00 to $70.00.

In the report, Somaiya noted, “BioMarin announced positive results from POM-001, the Phase I/II trial of BMN-701 in Pompe disease and confirmed its intention to advance ‘701 into Phase II/III by YE13. Overall, we believe the data are positive, with patients achieving meaningful improvements in pulmonary function and greater proportion of super responders in 6MWD. However, we believe the bar for success was relatively low, given go/no-go criteria outlined on the 4Q call and Myozyme's modest efficacy. Additionally, we note some variability in the data including lack of change in select pulmonary function measures (FVC).”

BioMarin Pharmaceutical closed on Tuesday at $60.76.

Latest Ratings for BMRN

DateFirmActionFromTo
Mar 2015JefferiesMaintainsBuy
Feb 2015CitigroupMaintainsBuy
Feb 2015JP MorganMaintainsOverweight

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMRN)

Around the Web, We're Loving...